# YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

> **NCT05767892** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Suzhou Puhe Pharmaceutical Technology Co., LTD** · enrollment: 350 (estimated)

## Conditions studied

- Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** YK-209A tablet
- **DRUG:** Pemetrexed+carboplatin/Cisplatin

## Key facts

- **NCT ID:** NCT05767892
- **Lead sponsor:** Suzhou Puhe Pharmaceutical Technology Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-05-01
- **Primary completion:** 2025-07-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2023-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05767892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05767892, "YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05767892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*